Skip to content

Expression characteristics of bone morphogenetic protein-4 (BMP4) in blood circulation of arterial diseases and its correlation with inflammation and vascular injury

Expression characteristics of bone morphogenetic protein-4 (BMP4) in blood circulation of arterial diseases and its correlation with inflammation and vascular injury

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300067976
Enrollment
Unknown
Registered
2023-02-01
Start date
2023-02-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atherosclerosis

Interventions

Gold Standard:Thrombosis or occlusion of the distal abdominal trunk (including abdominal aorta, iliac artery and lower limb artery below the abdominal trunk) was diagnosed by CTA or arteriography.
Index test:bone morphogenetic protein-4/IL-6/IL-10/TNF-a/VE-cadherin

Sponsors

Xiangya Second Hospital of Central South University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Selection criteria of disease group: 1. Newly admitted patients diagnosed as arterial plaque, stenosis or occlusion 2. Age: 18 -70, male or female. 3. No recent operation or infection. Selection criteria of control group: 1. People who have been healthy in the past, have no medication, surgery, severe infection, pregnancy, etc. 2. All physical examination items such as routine hematuria, liver and kidney function, blood lipid, blood sugar, nail function, hormones, blood pressure, electrocardiogram, X-ray or CT chest film, abdominal B-ultrasound (female gynecological B-ultrasound) and lung function are normal.

Exclusion criteria

Exclusion criteria: 1. having a history of mental illness, unable to express themselves or refusing to participate voluntarily. 2. The patient was complicated with diabetes. 3. The patient was complicated with obesity, with body mass index (BMI) > 30kg/m2. 4. The patient has a history of long-term use of hormone/nonsteroidal anti-inflammatory drugs, etc.

Design outcomes

Primary

MeasureTime frame
bone morphogenetic protein-4;

Secondary

MeasureTime frame
IL-6;IL-10;TNF-a;VE-cadherin;

Countries

China

Contacts

Public ContactRuohong Chen

Xiangya Second Hospital of Central South University

chenronghong@csu.edu.cn+86 18684679009

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026